logo
Plus   Neg
Share
Email
Comment

VIVUS Says FDA Extends Qnexa PDUFA Date

VIVUS Inc. (VVUS) said Monday that the U.S. Food and Drug Administration has extended the Prescription Drug User Fee Act date for its review of the Qnexa New Drug Application by three months from April 17 to July 17, 2012.

On April 4, following the FDA's request, VIVUS submitted the Qnexa Risk Evaluation and Mitigation Strategy, which was considered a major amendment to the NDA. The submission consisted of proposed REMS materials.

Since the receipt date was within three months of the user fee goal date, the FDA is extending the Prescription Drug User Fee Act date by three months to provide time for a full review of the submission, the company noted.

The Qnexa NDA seeks approval for the treatment of obesity, including weight loss and maintenance of weight loss for obese patients with weight-related co-morbidities such as hypertension, type 2 diabetes or dyslipidemia.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Bank of America Corp. (BAC) reported a profit for the fourth-quarter of 2017 that declined about 50 percent from last year, hurt by a charge of $2.9 billion or $0.27 per share, related to the Tax Cuts and Jobs Act. Retail giant Walmart Wednesday announced the launch of an opioid disposal solution, known as DisposeRx, which will help in its fight against opioid abuse and misuse. The free first-of-its kind solution will be available in all company pharmacies, making the retailer the first national pharmacy chain to do so. ASML Holding NV reported higher profit and sales in its fourth quarter with increased system sales, despite weak gross margin. Going ahead, the company projects continued solid growth of sales and profitability in 2018. Separately, ASML said its Supervisory Board intends to appoint Roger Dassen as Executive Vice President and Chief Financial Officer, effective June 1.
comments powered by Disqus
Follow RTT